Expand all sections

Tislelizumab

Tevimbra

Extended indication Extension of indication to include treatment of adult patients with non-small cell lung cancer (NSCL
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Tislelizumab
Domain Oncology
Reason of inclusion Indication extension
Main indication Lung cancer
Extended indication Extension of indication to include treatment of adult patients with non-small cell lung cancer (NSCLC) in combination and as monotherapy
Proprietary name Tevimbra
Manufacturer BeiGene
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date April 2024
Expected Registration February 2025
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.